Skip to content
Catalyst

metforminFinding

Metformin decreases all-cause mortality

lowersModerate evidenceFindingreplicated ×1

01 · The sentence it was drawn from

“Before weighting, the 30-day and five-year mortalities after surgery were lower in the metformin group than in the non-metformin group (0.3% vs. 1.0%; P < 0.001 for 30-day mortality and 13.6% vs. 19.7%; P < 0.001 for five-year mortality).”
Quoted verbatim from Association of preoperative metformin use with postoperative mortality and morbidity in type 2 diabetes patients undergoing noncardiac surgery: a retrospective cohort study.
This finding among the 158 findings on its endpoint

metformin

All-cause mortality

lowers

Who
adults with type 2 diabetes undergoing noncardiac surgery, metformin users vs non-users; secondary endpoint, unadjusted (before IPTW weighting), five-year follow-up horizon
Dose studied
not reported

Moderate evidencePMID 41208045 · 2026

02 · The study

Study
cohort
Duration
not reported

Evidence, by strength

  • strong
  • moderatethis finding
  • limited
  • very limited
  • insufficient

04 · To cite this finding

This address does not change

https://catalystproject.ai/e/01M3RHTEZPNAA899PJWEBA9JV4